Ikarian Capital’s Quince Therapeutics QNCX Stock Holding History

Ikarian Capital’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.31M	Buy	+72,251	New	+$1.66M	0.14%	99
2021 Q4	–	Sell	-101	Closed	-$1.85M	–	226
2021 Q3	$1.85M	Sell	101 -2	-2%	-$31.8K	0.13%	130
2021 Q2	$1.09M	Buy	+103	New	+$864K	0.09%	156
2021 Q1	–	Sell	-65	Closed	-$361K	–	327
2020 Q4	$361K	Sell	65 -135	-68%	-$1.2M	0.02%	202
2020 Q3	$2M	Buy	+200	New	+$1.82M	0.14%	113
2020 Q2	–	Sell	-125	Closed	-$1.14M	–	202
2020 Q1	$1.14M	Buy	+125	New	+$1.23M	0.09%	115

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ikarian Capital's QNCX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Quince Therapeutics (QNCX) in Q2 2026: 72,251 shares worth $1.31M. The stake represents 0.14% of the portfolio and ranks #99 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in QNCX as recently as Q3 2021.

Ikarian Capital first reported a position in QNCX in Q1 2020 and has held it in 6 quarters since. The position peaked at $2M in Q3 2020. 27 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

Ikarian Capital held 72,251 shares of Quince Therapeutics worth $1.31M as of Q2 2026.
Quince Therapeutics was a new Ikarian Capital position in Q2 2026.
Quince Therapeutics made up 0.14% of Ikarian Capital's portfolio in Q2 2026, its #99 holding.
Ikarian Capital first reported a position in Quince Therapeutics in Q1 2020 and has held it in 6 quarters since.
Ikarian Capital's Quince Therapeutics position peaked at $2M in Q3 2020.
27 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.